Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors
Sponsor: SystImmune Inc.
Summary
The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.
Official title: SI-B037-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B037 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2026-08-24
Completion Date
2029-11
Last Updated
2026-11-17
Healthy Volunteers
No
Conditions
Interventions
SI-B037
SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks
Locations (1)
NEXT Oncology
Houston, Texas, United States